ScreenerHero

RNTX Rein Therapeutics Inc.

NAS · US · Healthcare · Biotechnology · reintx.com
0.7887USD-4.40%Mkt Cap: 68.04M $P/E: —

Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap68.04M USD
Enterprise Value75.53M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-49.87M USD
Revenue/Share—
Last Price0.7887 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees10
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-3.64
EV/Revenue—
P/S—
P/B6.93
EPS (TTM)-1.69
EPS (Forward)—
52W Range
0.69406% of range2.180
52W High2.180 USD
52W Low0.6940 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE177.56%
ROA-206.44%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-19.36M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-11.44%
Net Debt-40.65M USD
Net Debt/EBITDA1.96
Balance Sheet
Debt/Equity—
Current Ratio4.27
Quick Ratio4.19
Book Value/Sh0.12 USD
Cash/Share0.47 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:20
Split DateNov 11, 2022
Analyst Consensus
Rating—
Target (Mean)6.000 USD
Upside (mean)+660.7%
Target Range4.000 USD – 8.000 USD
4.000+660.7% to mean8.000
# Analysts2
Ownership
Shares Out.86.27M
Float65.94M
Insiders5.02%
Institutions52.37%
Short Interest
Short Ratio1.3d
Short % Float0.78%
Short % Out.0.78%
Shares Short670.75K
Short (prev mo.)735.37K
Technical
SMA 500.7866 (+0.3%)
SMA 2001.092 (-27.8%)
Beta1.35
S&P 52W Chg16.45%
Avg Vol (30d)397.90K
Avg Vol (10d)383.24K
Technical Indicators
RSI (14)48.7
MACD-0.0003
MACD Signal-0.0062
MACD Hist.+0.0059
BB Upper0.8854 USD
BB Middle0.7954 USD
BB Lower0.7054 USD
BB Width22.63%
ATR (14)0.0696 USD
Vol Ratio (20d)1.09x